Prevention of chemotherapy-induced nausea and vomiting (CINV) is crucial in maximizing patients' quality of life and optimizing outcomes of cancer therapy, and can be done more effectively than ever before. Appropriate antiemetic therapy combined with targeted patient education, clear communication, and management of patient expectations results in optimal emetogenic control. Oncology nurses play a critical role in the prevention and management of CINV. This column reviews the history and pathophysiology of treatments for CINV, as well as patient-and chemotherapy-specific risk factors that should be considered to optimize treatment outcomes in patients with CINV.
S
imilar to realtors' mantra of "location, location, location," oncology nurses should have the mantra "prevention, prevention, prevention" foremost on their minds when assessing and developing a plan of care for controlling chemotherapy-induced nausea and vomiting (CINV). Patients with cancer often approach chemotherapy treatment with preconceived ideas about what their experience will entail. Many recall difficult experiences of older family members who received treatment before the development of newer antiemetic regimens. Despite advances in oncology care, many people still believe that all patients who receive chemotherapy will experience intractable vomiting.
According to the National Comprehensive Cancer Network (NCCN, 2012a) , prevention of nausea and vomiting is the primary goal of antiemetic treatment for all patients receiving cancer therapy. Patients who experience nausea or vomiting despite the use of prophylactic antiemetics frequently require additional medications, hydration, and sometimes hospitalization. Poorly controlled nausea or vomiting associated with chemotherapy increases risk of developing anticipatory nausea and vomiting, which ranges from 18%-57% in incidence (NCCN, 2012a) . The primary strategy in treating anticipatory nausea and vomiting is prevention through the consistent use of optimal antiemetic therapy beginning with the initial cycle of treatment (NCCN, 2012a) .
Prevention of CINV is pivotal when attempting to maximize patient quality of life during treatment. A study of patients with breast cancer who received aggressive antiemetics demonstrated improved appetite, better control of nausea and vomiting, and subsequent improved quality of life (Roldán et al., 2008) . Patients receiving chemotherapy with a goal of cure must receive full doses of standard chemotherapy on schedule to achieve optimal outcomes (Bonadonna et al., 2005) . Management of symptoms, including nausea and vomiting, is crucial to preventing delays in treatment related to dehydration or hospitalizations.
Background
The stereotypes of intractable nausea and vomiting related to chemotherapy originated in past decades when the only available antiemetics were corticosteroids and drugs such as dopamine receptor antagonists, metoclopramide, phenothiazines, and antihistamines. Those agents were significantly less effective than the 5-hydroxytryptamine (5-HT 3 ) receptor antagonists that were approved for use in the 1990s (Saito & Tsukuda, 2010) . Although the Colorectal (Tournigand et al., 2004) FOLFOX 6 67 42
Lung (Mok et al., 2009) Carboplatin + paclitaxel 44 33
Ovarian (Vasey et al., 2004) Carboplatin + docetaxel 78 37
FOLFOX 6-oxaliplatin + leucovorin + 5-fluorouracil; TAC-docetaxel + doxorubicin + cyclophosphamide availability of the receptor antagonist drugs allowed dose-dense therapies to be used in an effort to maximize outcomes of chemotherapy (Norton, 2001) , the relatively high incidence of nausea and vomiting reported in clinical trials indicates that CINV remains a problem in oncology treatment. In 2003, the first neurokinin 1 (NK1) receptor antagonist, aprepitant (Emend ® ), was approved by the U.S. Food and Drug Administration (Merck & Co., Inc., 2011) , introducing a new pathway for antiemesis treatment. The introduction of aprepitant placed a new emphasis on understanding the pathophysiology and the impact of delayed nausea and vomiting on the patient experience (Saito & Tsukuda, 2010) . Table 1 depicts the incidence of nausea and vomiting reported in major trials of key regimens in breast, colorectal, lung, and ovarian cancers.
Pathophysiology
The two most important neurotransmitters involved in vomiting are serotonin and substance P (Hesketh et al., 2003) . The emetic response to chemotherapy associated with these two neurotransmitters involves two separate pathways (Berger & Clark-Snow, 2005; Grunberg & Hesketh, 1993; Tavorath & Hesketh, 1996) (see Figure 1) . The peripheral pathway, which is located primarily in the gastroinis required to achieve optimal control of CINV (Hesketh et al., 2003) .
The serotonin-dependent mechanisms predominate during the initial time period after administration, specifically in the first 8-12 hours (Tavorath & Hesketh, 1996) (see Figure 2) . The acute events responsive to 5-HT3 receptor antagonists likely are mediated by serotonin release in the gastrointestinal tract via the peripheral pathway. Therefore, 5-HT3 receptor antagonists, such as granisetron
, block serotonin and all are equally effective in the peripheral pathway in counteracting acute CINV (NCCN, 2012a). As substance P becomes more active in the pathogenesis of delayed CINV (about 16 hours after chemotherapy administration), the effectiveness of the 5-HT3 antagonists diminishes and the need for treatment targeting the central pathway becomes important.
Medical Treatment
Understanding the different roles of these neurotransmitters in each of the distinct emetic pathways and corresponding phases supports the use of combination antiemetic regimens to achieve maximum prevention of CINV. The 5-HT3 receptor antagonists are active in the peripheral pathway and counteract acute nausea and vomiting by blocking serotonin activity. Palonosetron (Aloxi ® ), a second-generation 5-HT3 receptor antagonist, also works in the gastrointestinal tract on the peripheral pathway. testinal tract, is associated primarily with acute-onset CINV and is mediated by serotonin. Acute-onset CINV occurs within a few minutes to several hours after drug administration and commonly resolves within the first 24 hours (NCCN, 2012a). Chemotherapy causes the release of serotonin, which binds to 5-HT3 receptors and sends signals through the chemoreceptor trigger zone to the vomiting center in the medulla, resulting in CINV (Hesketh et al., 2003) . The central pathway, which is located primarily in the brain, is associated with delayed-onset CINV. Delayed-onset CINV develops in patients more than 24 hours after chemotherapy administration and may last for up to a week (NCCN, 2012a Although palonosetron is unique in its long half-life (about 40 hours, compared with four hours with ondansetron), it remains primarily effective in the acute phase (Eisai, 2009) . After the first 8-12 hours of serotoninmediated events, the NK1 -dependent mechanisms have greater importance. Emetic events in the late acute phase and in the delayed phase are most likely mediated by substance P acting centrally on NK1 receptors. The only NK1 receptor antagonist drugs currently available are aprepitant and fosaprepitant, which have a high affinity for NK1 receptors.
Patient-Specific Risk Factors
Characteristics that increase a patient's risk of developing CINV include sex, age, and patient history (Hesketh, 1999; Navari, 2003; NCCN, 2012a; Osoba et al., 1997; Roila, Hesketh, & Herrstedt, 2006; Schwartzberg, 2007 ) (see Figure  3) . Female patients are reported to have more significant problems with CINV than their male counterparts (Navari, 2003; Osoba et al., 1997; Schwartzberg, 2007) . In one study, 41% of women had a complete response from their antiemetic regimen compared with 53% of men who received the same chemotherapy and antiemetic regimens (Hesketh et al., 2006) . Adult patients younger than 65 years have a higher risk of developing CINV than patients older than 65 years. Many older adult patients experience more significant CINV during the delayed phase than the acute phase (Jakobsen & Herrstedt, 2009 ). Other patient characteristics associated with increased risk of CINV include a history of motion sickness or morning sickness accompanied by nausea and vomiting; postoperative, radiation-related, or chemotherapyrelated nausea and vomiting; and alcohol consumption of less than 1.5 oz per day (Schwartzberg, 2007) .
Chemotherapy-Specific Risk Factors
After reviewing the patient's unique individual characteristics, the emetogenicity of the chemotherapeutic agents in the regimen prescribed must be considered. Although many practices think of only cisplatin-containing regimens as having high emetogenicity, NCCN considers any platinum analog-containing regimens to be moderately to highly emetogenic (NCCN, 2012b-h) (see Table 2 ). The length of infusion time, number of chemotherapy cycles, and emetogenic potential of each drug in the regimen also are predictive of risk. Experienced oncology nurses recognize that patients who receive repeated cycles of chemotherapy also have increased incidence of CINV (Roila et al., 2006) . Keeping that in mind, a successful emetogenic care plan should not be changed in later cycles. Chemotherapy regimens with multiple drugs may compound the risk of acute and delayed CINV. NCCN recommends selecting the antiemetic therapy based on the drug with the highest emetic risk within the prescribed regimen. Regimens with multiple low-risk or moderate-risk drugs may actually pose a high risk of CINV because the combination of drugs joined with the patient risk factors increases the risk of emesis (Polovich, Whitford, & Kelleher, 2009).
Care Plan Guiding Principles
When creating a comprehensive antiemetic care plan, nurses must carefully consider two categories of risk factors that may affect a patient's risk of CINV: those that are unique to the individual patient and those that are characteristic of the chemotherapy regimen prescribed. NCCN and the American Society of Clinical Oncology have provided basic, evidence-based guidelines to assist with developing a comprehensive antiemetic care plan (Basch et al., 2011; NCCN, 2012a) . Prevention of all phases of emesis is the main goal of any antiemetic plan. The plan must begin with the first cycle to reduce the risk of anticipatory CINV and should continue throughout all cycles of treatment. The plan must account for whether the drugs in the regimen are known to have both acute-onset and delayed-onset CINV potential or acute-onset CINV potential only. Patients receiving regimens with potential for delayed-onset CINV should receive an NK1 receptor antagonist to Note. Based on information from Hesketh, 1999; National Comprehensive Cancer Network, 2012a; Navari, 2003; Osoba et al., 1997; Roila et al., 2006; Schwartzberg, 2007. effectively target the central pathway. Combining the medications that act on different neurotransmitters allows for coverage for both acute-onset and delayed-onset CINV.
Patients at high risk for CINV should receive a combination of a 5-HT3 antagonist, an NK1 antagonist, and a corticosteroid before chemotherapy. Patients considered to have moderate risk levels should at least receive a combination of a corticosteroid and 5-HT3 antagonist, and the addition of an NK1 antagonist should be considered whenever a patient has multiple personal risk factors and/or when delayed-onset CINV is a possibility (NCCN, 2012a) .
For patients who experience anticipatory CINV despite best efforts, treatment with lorazepam or alprazolam as well as nonpharmacologic interventions (e.g., relaxation techniques) may be considered. For patients who experience breakthrough CINV, the plan for subsequent cycles should be reconsidered, either increasing to a higher level of emetic control or adding drugs from another classification to treat CINV (NCCN, 2012a).
Nursing Implications
A thorough patient history and careful assessment of patient risk factors are the first steps to providing an effective antiemetic plan. Nurses, working collaboratively with pharmacists, medical staff, social workers, and nutritionists, can create institutional practice guidelines and individual plans that provide the highest standard of care for patients. Nurses are well positioned to be strong patient advocates by ensuring appropriately prescribed antiemetics that cover the entire period of emetic risk and consider patients' individual risk factors.
A personalized education plan, combined with patient education tools (see Figure 4) , is essential to patient understanding of the plan of care once at home. As most chemotherapy is delivered on an outpatient basis, patients need clear instructions regarding how to take antiemetics and when to alert the oncologist or oncology nurse about uncontrolled CINV.
One study found that about 75% of patients older than 50 years were adherent to their antiemetic regimen, whereas only half of younger patients adhered to the prescribed antiemetic regimen (Shih, Wan, & Chan, 2009) . Focused education needs to be provided to younger patients, discussing consequences related to inadequate emetic control and addressing concerns about side effects. Patients with three or more risk factors also tend to be more adherent, suggesting that they recognize their own emetic risk and the need for appropriate treatment (Shih et al., 2009) .
Nurses need to assess patient financial concerns and assist patients with reimbursement issues or refer them to financial counseling or social work as needed. Barriers to adherence to the antiemetic plan need to be assessed and addressed before treatment begins.
Conclusions
Nurses are uniquely positioned to positively impact prevention and management of CINV. Through increased understanding of the pathophysiologic mechanisms involved in CINV and development of medications targeting those mechanisms, CINV can be prevented more effectively than ever before. Assessment of emetogenic potential and individual patient risk factors is essential to creating an emetogenic care plan that meets patient needs. Antiemetic therapy combined with individualized patient education, clear communication, and the management of expectations positions patients to achieve optimal emetogenic control. Providing an effective antiemetic regimen may improve patient adherence to the chemotherapy regimen prescribed and foster completion of treatment.
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